FTO基因在乳腺癌组织的表达及新辅助化疗对其表达的影响

FTO gene expression in breast cancer tissue before and after neoadjuvant chemotherapy

目的:探讨FTO基因在原发性乳腺癌组织中的表达及新辅助化疗对其表达的影响。方法:应用RT-PCR方法检测28例乳腺增生病组织和24例乳腺癌组织及10例乳腺癌新辅助化疗前后组织中FTO mRNA的表达水平,并分析FTO基因表达水平与乳腺癌患者临床病理参数的关系。结果:FTO基因在乳腺增生组织及乳腺癌组织均有表达,而在乳腺癌表达高于乳腺增生组织(P<0.05);新辅助化疗后乳腺癌组织FTO mRNA的表达水平低于化疗前(P<0.05);乳腺癌组织FTO mRNA表达水平与淋巴结转移有关,FTO mRNA的表达量在淋巴结转移组高于未转移组(P<0.05),而与ER,PR受体,CerbB-2基因状态及肥胖无关(均P>0.05)。结论:FTO基因在乳腺癌组织中表达增加,且可能与乳腺癌发生发展有关;新辅助化疗可以下调乳腺癌组织FTO基因的表达。

Objective： To investigate the expression of FTO （fat mass and obesity associated） gene in breast cancer tissue and the influence of neoadjuvant chemotherapy on its expression. Methods： The FTO mRNA expressions in 28 cases of hyperplastic breast tissues, 24 cases of breast cancer tissues and 10 pairs of breast cancer tissues taken before and after neoadjuvant chemotherapy were determined by RT-PCR method. In addition, the relations of the expression level of FTO mRNA with the clinicopathologic parameters of the breast cancer patients were analyzed. Results： FTO mRNA was expressed in both hyperplastic breast tissue and breast cancer tissue, but its expression level in breast cancer tissues was significantly higher than that in hyperplastic breast tissue （P〈0.05）. The expression level of FTO mRNA in breast cancer tissue after neoadjuvant chemotherapy was lower than that before neoadjuvant chemotherapy （P〈0.05）. The expression level of FTO mRNA was associated with lymphatic metastasis, which was higher in the patients with lymphatic metastasis than that in patients without lymph node involvement （P gene or the degree of obesity 〈0.05）, while it was not relevant to of the patients （all P〉0.0S）. the status of ER and PR receptors, CerbB-2 Conclusion： FTO expression is increased in breast cancer tissues, which may probably be associated with the occurrence and development of breast cancer; FTO mRNA expression in breast cancer tissues can be reduced by neoadjuvant chemotherapy.